Firibastat

A drug under investigation for the treatment of hypertension

Firibastat
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Firibastat is an investigational drug being studied for its potential use in the treatment of hypertension. It is a prodrug that is converted in the body to its active form, EC33, which acts as an inhibitor of the enzyme aminopeptidase A. This enzyme is involved in the renin-angiotensin system, which plays a critical role in the regulation of blood pressure.

Mechanism of Action

Firibastat is designed to target the brain's renin-angiotensin system by inhibiting aminopeptidase A. This inhibition prevents the conversion of angiotensin II to angiotensin III, which is a potent vasopressor and stimulates the release of aldosterone. By reducing the levels of angiotensin III, firibastat helps to lower blood pressure.

Development and Clinical Trials

Firibastat is being developed by Quantum Genomics, a biopharmaceutical company focused on developing treatments for cardiovascular diseases. The drug has undergone several phases of clinical trials to evaluate its safety and efficacy in patients with hypertension.

Phase I Trials

The initial phase I trials of firibastat were conducted to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. These studies demonstrated that firibastat was well-tolerated and provided the necessary data to proceed to further clinical testing.

Phase II Trials

In phase II trials, firibastat was tested in patients with hypertension to evaluate its efficacy in reducing blood pressure. The results showed a significant reduction in systolic and diastolic blood pressure, supporting its potential as a treatment for hypertension.

Phase III Trials

Phase III trials are ongoing to further assess the long-term safety and efficacy of firibastat in a larger population of patients with hypertension. These studies aim to confirm the findings of earlier trials and provide the data needed for regulatory approval.

Potential Benefits

Firibastat offers a novel approach to the treatment of hypertension by targeting the central nervous system's renin-angiotensin system. This mechanism of action is different from traditional antihypertensive drugs, which often target peripheral components of the system. As a result, firibastat may provide an alternative for patients who do not respond well to existing treatments.

Side Effects

The side effects of firibastat observed in clinical trials have generally been mild and transient. Common side effects include headache, dizziness, and fatigue. Ongoing studies continue to monitor the safety profile of the drug.

Related Pages

• Hypertension
• Renin-angiotensin system
• Aminopeptidase A
• Antihypertensive drug